Yeşil C, Kandemir O, Haksever H, Dabakoğlu T
Atatürk Training and Research Hospital Pathology Department, Ankara, Turkey.
Acta Chir Belg. 2015 Jul-Aug;115(4):299-305. doi: 10.1080/00015458.2015.11681116.
Even though morphologic findings are generally important in the diagnosis of thyroid tumors, in some cases, morphologic similarities between benign and malignant lesions lead to noticeable differences in evaluation and different diagnoses in the same cases. In our study, we researched whether the autophagy-related protein Beclin-1 (BECN1) is a diagnostic marker in thyroid tumors, as well as its correlation with HBME-1, which has high sensitivity and specificity in distinguishing malignant thyroid lesions.
Samples from 136 patients that received a thyroidectomy were fixed in 10% formalin. All cases had hematoxylin & eosin (H&E) stains available for review and paraffin blocks for immunohistochemical staining. In immunochemistry tests, BECN1, HBME-1, and Ki-67 were studied.
BECN1 immunoreactivity rates were found to be 98.9% in papillary thyroid carcinoma (PTC), 57.1% in follicular carcinoma (FC), and 21.4% in follicular adenoma (FA). HBME-1 immunoreactivity was 100% in PTC, 85.7% in FC, and 64% in FA. In thyroid carcinomas, BECN1 was as effective as HBME-1 as a marker for the diagnosis of malignancy.
We revealed an important role of autophagy in thyroid carcinogenesis, as evidenced by the high rate of BECN1 immunoreactivity in PTC and FC. Moreover, we found that autophagy plays a more important role in PTC, as evidenced by the high immunoreactivity rates. According to our results, BECN1 is a more specific marker than HBME-1 in PTC and has a higher correlation with Ki-67. In routine studies, BECN1 will be more helpful than HBME-1 in the diagnosis of PTC.
尽管形态学发现通常在甲状腺肿瘤的诊断中很重要，但在某些情况下，良性和恶性病变之间的形态学相似性会导致评估上的显著差异以及同一病例出现不同诊断结果。在我们的研究中，我们研究了自噬相关蛋白Beclin-1（BECN1）是否为甲状腺肿瘤的诊断标志物，以及它与HBME-1的相关性，HBME-1在鉴别甲状腺恶性病变方面具有高敏感性和特异性。
对136例行甲状腺切除术患者的样本用10%中性福尔马林固定。所有病例均有苏木精-伊红（H&E）染色切片可供复查，并制备石蜡块用于免疫组化染色。在免疫组化检测中，研究了BECN1、HBME-1和Ki-67。
发现BECN1免疫反应率在甲状腺乳头状癌（PTC）中为98.9%，在滤泡状癌（FC）中为57.1%，在滤泡性腺瘤（FA）中为21.4%。HBME-1免疫反应率在PTC中为100%，在FC中为85.7%，在FA中为64%。在甲状腺癌中，BECN1作为恶性肿瘤诊断标志物与HBME-1效果相当。
我们揭示了自噬在甲状腺癌发生中的重要作用，PTC和FC中BECN1高免疫反应率证明了这一点。此外，我们发现自噬在PTC中起更重要的作用，高免疫反应率证明了这一点。根据我们的结果，BECN1在PTC中是比HBME-1更具特异性的标志物，并且与Ki-67具有更高的相关性。在常规研究中，BECN1在PTC的诊断中比HBME-1更有帮助。
